Neurotech Insights - Epilepsy Issue. Brain Waves: The field of neurotechnology, the focus of this blog, encompasses advances in brain science (neurons), information technology (bits) and bioengineering (genes). Up for discussion and analysis: the political, economic, ethical, and social forces that will shape the future of what will be one of the most important and fascinating stories of the coming decades.

About this author

Zack Lynch is author of The Neuro Revolution: How Brain Science Is Changing Our World (St. Martin's Press, July 2009).
He is the founder and executive director of the Neurotechnology Industry Organization (NIO) and co-founder of NeuroInsights. He serves on the advisory boards of the McGovern Institute for Brain Research at MIT, the Center for Neuroeconomic Studies, Science Progress, and SocialText, a social software company. Please send newsworthy items or feedback - to Zack Lynch.
Follow me on Twitter at @neurorev

Receive by email

GUEST AUTHOR ARCHIVES

In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

« Guilty By Reason of 'My Neurons Made Me Do It' | Main | Trust, Happiness and Societal Development »

August 1, 2006

Neurotech Insights - Epilepsy Issue

Posted by Zack Lynch

In case you wonder why I don't blog every day, here is an overview of this month's Neurotech Insights which has a special focus on emerging treatments for epilepsy.

Emerging Epilepsy Treatments: Each month Neurotech Insights provides an in-depth review of a specific brain-related illness. This month we focus on Epilepsy, reviewing the different types of epilepsy, current treatments, and therapies in the pipeline. Drugs and devices covered in this article include those from D-Pharm, Teva, Abbott, Novartis, NeuroSearch, Valeant, GSK, UCB, Eisai, Cyberonics, Neuropace and more...

JULY MARKET HIGHLIGHTS
* Prana Biotechnology's (PRNA) stock price nearly doubled on speculation that its PBT2 compound has potential to treat Alzheimer's disease. >>>
* Northstar Neuroscience (NSTR) was up 28% after completing enrollment in their cortical stimulation study to promote neuroplasticity following stroke and signing an agreement with AMI Semiconductor.
* Several private companies closed large financings including obesity device maker, Enteromedics with a $45 million Series C and Prestwick Pharmaceuticals with a $60 million Series C.

For 18 additional stories from this month's Neurotech Insights click here.

CNS Product & Clinical Trial Updates
* Acadia (ACAD) Announces Encouraging Results for Schizophrenia
* Shinogi Gets Favorable Phase II Results in Obesity
* Myriad (MYGN.O) Says Flurizan Alzheimer's Study Positive

200_Neurotech_Insights_July_31_2006_Epilepsy_Page_01_web.jpg For more details and updates on TorreyPines Therapeutics, Shire (SHPGY), Astellas, AstraZeneca (AZN), Neuro-HiTech, Somaxon (SOMX), Amarin (AMRN), and more click here.

Deals, Alliances, & Financings
* Evotec and Roche Form CNS Alliance
* Athenagen and Zapaq Agree on Merger
* Northstar (NSTR) to work with AMI Semiconductor
* Memory (MEMY) Hits Roche Milestone

For more stories on Enteromedics, Lilly (LLY), Alcon (ACL), Neuromed, Prestwick Pharmaceuticals and others click here.

Featured Company: NeuroSearch A/S

In our monthly CEO interview series, we check in with NeuroSearch's CEO Flemming Pedersen to get an insider perspective on the Danish company's in-house product development programs.

Public Neurotech Index

As of July 31st, the Neurotech Index, which was started Dec 31, 2003, is up 42%, compared to respective gains of 15% and 4% for the S&P 500 and the NASDAQ Composite Index. The Neurotech Index is also outpacing the NASDAQ Biotech Index, another life-sciences-oriented measure of the public markets, which has gained only 1% during the same period.

Subscribe to Neurotech Insights

Neurotech Insights is published by NeuroInsights on the last day of each month, and provides in depth feature articles, private company news, product development tracking, executive interviews, and public stock commentary based on a deep and intimate understanding of the commercial neuroscience industry players and products. Neurotech Insights provides the most relevant competitive intelligence on the neurotechnology industry covering recent advances in drugs, devices and diagnostics for brain and nervous system illnesses. Save over 25% on each issue by ordering a 12 month subscription. Subscribe to Neurotech Insights today.

Comments (0) + TrackBacks (0) | Category: NeuroInsights

POST A COMMENT

Thanks for signing in, . Now you can comment. (sign out)

(If you haven't left a comment here before, you may need to be approved by the site owner before your comment will appear. Until then, it won't appear on the entry. Thanks for waiting.)